Aminophylline Anhydrous

證據等級: L5

預測適應症: 0 個

Aminophylline Anhydrous: Bronchodilator with Insufficient Repurposing Data

One-Sentence Summary

Aminophylline Anhydrous is a methylxanthine bronchodilator classically used for bronchial asthma and chronic obstructive pulmonary disease (COPD). No TxGNN repurposing predictions are currently available for this drug — the predicted_indications field is empty — meaning no new indication target and no supporting evidence can be reported at this time. This report documents the current data status and outlines remediation steps before a full repurposing evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Bronchial asthma / COPD / Acute bronchospasm (based on known pharmacology; package insert text not retrieved)
Predicted New Indication	— (No TxGNN prediction available)
TxGNN Prediction Score	—
Evidence Level	L5 (Model prediction not yet generated)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for this candidate at the time of report generation (predicted_indications: []). Therefore, a mechanistic link to any new indication cannot be evaluated.

From established pharmacology, Aminophylline is a 2:1 complex of theophylline and ethylenediamine. Theophylline acts primarily as a non-selective phosphodiesterase (PDE) inhibitor, raising intracellular cAMP and cGMP levels, leading to bronchial smooth muscle relaxation. It also acts as an adenosine receptor antagonist (A1, A2A), which accounts for secondary effects including positive chronotropy, mild diuresis, and central respiratory stimulation.

These pleiotropic mechanisms — particularly adenosine antagonism and anti-inflammatory effects via PDE4 inhibition — have historically generated interest in repositioning xanthines toward neurological, cardiological, and inflammatory conditions. However, without TxGNN scores or supporting evidence, no specific repurposing candidate can be recommended at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered for a predicted new indication (prediction data unavailable).

Literature Evidence

Currently no related literature available for a predicted new indication (prediction data unavailable).

Malaysia Market Information

The Evidence Pack reports 1 active registration in Malaysia, but all license detail fields (authorization number, product name, dosage form, manufacturer, approved indication text) were returned as empty strings. The following is a placeholder pending data retrieval:

Authorization Number	Product Name	Dosage Form	Approved Indication
(Pending retrieval)	Aminophylline Anhydrous	(Pending)	(Pending — download package insert from NPRA portal)

Action required: Query the NPRA product database directly for the single registered product to populate these fields.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug interactions) were returned as [Data Gap] or empty. The following known safety concerns are documented in international references and should be verified against the Malaysian-approved package insert before clinical use:

Narrow therapeutic index: Theophylline serum levels must be monitored (target 10–20 µg/mL; toxicity above 20 µg/mL).

Cardiovascular: Tachycardia, arrhythmia, and hypotension risk — use with caution in cardiac disease.

CNS: Seizures reported at toxic concentrations.

Drug interactions: Multiple significant interactions (e.g., with ciprofloxacin, cimetidine, rifampicin, phenytoin) that alter theophylline clearance; DDI module returned 0 results and requires re-query.

These are reference observations only and do not substitute for the approved local label.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline has not returned any repurposing candidates for Aminophylline Anhydrous, making it impossible to identify a new indication, assess mechanistic plausibility, or evaluate supporting evidence. The safety profile cannot be formally reviewed until the package insert is retrieved.

To proceed, the following is needed:

Re-run TxGNN prediction — Confirm that AMINOPHYLLINE ANHYDROUS is correctly mapped to its DrugBank entry (theophylline: DB00277; aminophylline: DB01223) and re-execute the KG and DL prediction pipelines to populate predicted_indications.
Resolve DrugBank ID — drugbank_id is null; link to DrugBank DB01223 (aminophylline) or DB00277 (theophylline) to unlock MOA, toxicity, and DDI data.
Retrieve NPRA package insert — Download and parse the PDF from the NPRA portal to populate approved_indication_text, warnings, and contraindications (Data Gaps DG001, DG002).
Populate license details — The single registration record has all fields empty; retrieve product name, dosage form, and manufacturer from the NPRA database.
Re-query DDI module — Once DrugBank ID is resolved, re-run the drug–drug interaction query to replace the empty interactions array.
Re-issue this report after the above data gaps are resolved to enable a full L1–L5 evidence grading and a substantive Go / Proceed with Guardrails decision.

⚠️ This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate requires clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.